阿弗利塞普特2毫克生物类似剂 (Tyalia) -来自伊朗的现实世界经验 (ATRIA研究)
Sahar Avadzadeh1, Ashish Sharma2, Mohammad Mehdi Parvaresh3
1Faculty of Medicine, Tehran Medical Sciences, Islamic Azad University, Tehran, Iran.
Eye (London, England)
|May 3, 2025
概括
这项研究发现aflibercept生物类似物Tyalia在视网膜疾病的实际使用中是安全和有效的. 早期的结果表明,Tyalia提供与原始aflibercept药物类似的结果.
科学领域:
- 眼科医生 眼科 眼科
- 视网膜疾病 视网膜疾病
- 药理学 药理学是指药理学的学科.
背景情况:
- 阿弗利伯塞普特2毫克是几种视网膜疾病的关键治疗方法.
- 评估生物类似药的疗效和安全性对于临床采用至关重要.
- 蒂亚利亚是一种由Cinnagen开发的aflibercept生物类似药.
研究的目的:
- 为了评估Tyalia的早期,现实世界的临床结果,aflibercept 2 mg生物类似剂.
- 评估Tyalia在患有视网膜疾病的患者的安全性和有效性.
主要方法:
- 一个追溯的,不受控制的观察性研究.
- 包括148名患者 (189只眼睛) 接受Tyalia 2mg静脉内注射.
- 症状包括神经血管与年龄相关的黄斑变性 (n-AMD),糖尿病黄斑 (DMO) 和视网膜静脉封闭 (RVO).
主要成果:
- 平均中央子场厚度 (CST) 显著改善 (p < 0.001).
- 最好的纠正视力敏度在整个队列中保持稳定.
- 观察到不良事件的发生率很低 (0.4%).
结论:
- 初步的现实世界数据表明,Tyalia的疗效和安全性与创新者aflibercept 2 mg.
- 需要对更大种群进行进一步的长期研究.
- 蒂亚利亚显示承诺作为一个安全和有效的治疗选项,用于已批准的适应症.
相关概念视频
01:16Bioequivalence: Overview
874
Pharmaceutical equivalents, by definition, are drug products with the same active ingredient in the same quantities, encapsulated in identical dosage forms, and intended for the same administration routes. These pharmaceutical equivalents are deemed bioequivalent if the bioavailability of the active entity in the drug preparations is similar. Moreover, pharmaceutical equivalents demonstrating bioequivalence are also regarded as therapeutically equivalent. This means that when used as directed,...
874
01:11Clinical Trials: Overview
2.4K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
2.4K